Literature DB >> 15824673

Novel therapies for sepsis: a review.

Katherine J Deans1, Michael Haley, Charles Natanson, Peter Q Eichacker, Peter C Minneci.   

Abstract

BACKGROUND: Over the past 30 years, efforts have been made to identify therapeutic targets in the host response to infection.
METHODS: A review of the randomized controlled clinical sepsis trials and meta-analyses of glucocorticoids, mediator-specific anti-inflammatory agents, and anticoagulant agents was performed.
RESULTS: The effects of glucocorticoids in sepsis appear to be dose-dependent, with high doses decreasing survival and low doses improving survival. As a class, the mediator-specific anti-inflammatory agents have a small beneficial effect on survival; however, no single agent has demonstrated significant benefit. The treatment effects of these agents appear to be related to the patient's risk of death. As a class, the anticoagulant agents do not improve survival; however, the efficacy of these agents may have been confounded by concurrent heparin therapy. Activated protein C demonstrated a beneficial effect on survival that was dependent on severity of illness.
CONCLUSION: Trials of agents directed at altering the host's response during sepsis have had variable results, and it appears that several different factors may alter the efficacy of these agents.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15824673     DOI: 10.1097/01.ta.0000158244.69179.94

Source DB:  PubMed          Journal:  J Trauma        ISSN: 0022-5282


  46 in total

1.  Mechanisms of sepsis and insights from clinical trials.

Authors:  Nitin Seam; Anthony F Suffredini
Journal:  Drug Discov Today Dis Mech       Date:  2007

2.  Stratification is the key: inflammatory biomarkers accurately direct immunomodulatory therapy in experimental sepsis.

Authors:  Marcin F Osuchowski; Judith Connett; Kathleen Welch; Jill Granger; Daniel G Remick
Journal:  Crit Care Med       Date:  2009-05       Impact factor: 7.598

3.  Circulatory effects of dexmedetomidine in early sepsis: a randomised controlled experimental study.

Authors:  Zoi Aidoni; Chryssa Pourzitaki; Eleni Stamoula; Katerina Kotzampassi; Georgia Tsaousi; George Kazakos; Christophoros N Foroulis; Charisios Skourtis; Dimitrios G Vasilakos; Vassilios Grosomanidis
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-08-17       Impact factor: 3.000

4.  PD-L1 blockade improves immune dysfunction of spleen dendritic cells and T-cells in zymosan-induced multiple organs dysfunction syndromes.

Authors:  Qian Liu; Yi Lv; Min Zhao; Yiduo Jin; Jiangyang Lu
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

5.  Genomics of injury: The Glue Grant experience.

Authors:  Ronald G Tompkins
Journal:  J Trauma Acute Care Surg       Date:  2015-04       Impact factor: 3.313

Review 6.  A novel role for coinhibitory receptors/checkpoint proteins in the immunopathology of sepsis.

Authors:  Eleanor A Fallon; Bethany M Biron-Girard; Chun-Shiang Chung; Joanne Lomas-Neira; Daithi S Heffernan; Sean F Monaghan; Alfred Ayala
Journal:  J Leukoc Biol       Date:  2018-02-02       Impact factor: 4.962

7.  Chronic sepsis mortality characterized by an individualized inflammatory response.

Authors:  Marcin F Osuchowski; Kathy Welch; Huan Yang; Javed Siddiqui; Daniel G Remick
Journal:  J Immunol       Date:  2007-07-01       Impact factor: 5.422

8.  Local and systemic chemokine patterns in a human musculoskeletal trauma model.

Authors:  Daniel Bastian; Margareth Vislie Tamburstuen; Ståle Petter Lyngstadaas; Olav Reikerås
Journal:  Inflamm Res       Date:  2009-03-10       Impact factor: 4.575

9.  Influence of acute epinephrine infusion on endotoxin-induced parameters of heart rate variability: a randomized controlled trial.

Authors:  Badar U Jan; Susette M Coyle; Leo O Oikawa; Shou-En Lu; Steve E Calvano; Paul M Lehrer; Stephen F Lowry
Journal:  Ann Surg       Date:  2009-05       Impact factor: 12.969

Review 10.  Host defense peptides as effector molecules of the innate immune response: a sledgehammer for drug resistance?

Authors:  Lars Steinstraesser; Ursula M Kraneburg; Tobias Hirsch; Marco Kesting; Hans-Ulrich Steinau; Frank Jacobsen; Sammy Al-Benna
Journal:  Int J Mol Sci       Date:  2009-09-09       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.